1 / 1

Thyrotropin Alfa(Thyrogen)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

INJECTION

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

FASLODEX® (fulvestrant) is a prescription medication used to treat hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women. It can be administered as a monotherapy or in combination with targeted therapies such as ribociclib, palbociclib, or abemaciclib. The drug works by inhibiting the estrogen receptor, effectively blocking the growth of estrogen-dependent breast cancer cells. FASLODEX® is administered intramuscularly and has a carefully designed schedule of administration to optimize efficacy and reduce the risk of adverse effects.

This treatment is specifically designed for postmenopausal women who have either not received prior endocrine therapy or whose disease has progressed after initial endocrine treatment. FASLODEX® provides a critical therapeutic option for managing advanced breast cancer by targeting estrogen receptor signaling, a key pathway involved in tumor growth in hormone-sensitive cancers.

Generic name

Thyrotropin Alfa(Thyrogen)

English name

Thyrotropin Alfa

Alternative Names

Thyrogen

Drug prices

Indications

THYROGEN® (thyrotropin alfa) is indicated for the following conditions:

Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer:

THYROGEN-stimulated Tg levels are generally lower than and do not correlate with Tg levels after thyroid hormone withdrawal.

Risk of missing a diagnosis or underestimating the extent of disease, even when combined with radioiodine imaging.

Anti-Tg antibodies may interfere with Tg assay, rendering results uninterpretable.

Used as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.

Limitations:

Adjunct for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer:

Effect on thyroid cancer recurrence more than 5 years post-remnant ablation has not been evaluated.

Used as an adjunct for radioiodine ablation of thyroid tissue remnants in patients who have undergone near-total or total thyroidectomy for well-differentiated thyroid cancer and do not have evidence of distant metastatic thyroid cancer.

Limitations:

Effect on thyroid cancer recurrence more than 5 years post-remnant ablation has not been evaluated.

Therapeutic Target

The therapeutic target of THYROGEN® is to stimulate the thyroid gland through thyroid-stimulating hormone (TSH) for diagnostic purposes and as part of thyroid remnant ablation in thyroid cancer therapy.

Active Ingredients

Thyrotropin Alfa.

Dosage form

INJECTION

specifications

Lyophilized powder for injection Concentration: 0.9 mg of thyrotropin alfa per vial Packaging: Single-dose vial.

Description

THYROGEN® is a recombinant human thyroid-stimulating hormone (TSH) indicated for the treatment of well-differentiated thyroid cancer. It is used as an adjunct for serum thyroglobulin (Tg) testing or radioiodine imaging and as an adjunct in the ablation of thyroid remnants. It is available as a lyophilized powder that, when reconstituted, is administered intramuscularly.

Dosage and Administration

Recommended Dosage:

A two-injection regimen is recommended:

First dose: 0.9 mg of THYROGEN® intramuscularly.

Second dose: 0.9 mg of THYROGEN® intramuscularly 24 hours later.

Administration Details:

The drug must be administered under the supervision of a healthcare provider experienced in the management of thyroid cancer.

Reconstitution and Preparation: The powder must be reconstituted with the provided diluent, following the instructions in the product's full prescribing information.

Timing of Serum Tg Testing: Serum thyroglobulin testing should occur 24-72 hours after the second injection.

Timing for Remnant Ablation: Radioiodine treatment should be performed after THYROGEN® administration, following the recommended guidelines for such procedures.

CATEGORY NAVIGATION